Lung cancer drug sotorasib tested in chinese patients

NCT ID NCT07143513

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how safe sotorasib is for Chinese patients with a certain type of advanced lung cancer (KRAS G12C-mutated NSCLC). 102 patients who had already tried other treatments took sotorasib pills daily. Researchers tracked side effects and how long patients lived. The goal was to understand the drug's safety in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotorasib (a targeted cancer pill)
What this could lead to: If results are positive, this could confirm that sotorasib is safe and effective for Chinese patients with a specific type of lung cancer, supporting its use in this population.
What could go wrong: This is a completed real-world study, not a controlled trial, so results may be less reliable. Side effects like liver or lung problems are possible, and the drug only works for patients with a specific gene mutation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Boao Evergrande International Hospital

Qionghai, Hainan, 571400, China
Boao Super Hospital

Qionghai, Hainan, 571499, China
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital

Qionghai, Hainan, 57400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.